Phivida Holdings Inc. Completes Initial Public Offering: Will Begin Trading December 19th Under The Symbol VIDA
Phivida Holdings Inc. reports that it has completed its initial public offering and anticipates that its common shares will commence trading on the Canadian Securities Exchange on December 19, 2017 under the ticker symbol "VIDA".
Pursuant to the Offering, Phivida issued 14,375,000 units (the "Units"), including the full over-allotment option, with each Unit comprising one common share (each, a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant") at a price of $0.40 per Unit for gross proceeds of $5,750,000.
Each Warrant is exercisable at a price of $0.75 per Common Share for a period ending 24 months from the closing date of the Offering, subject to accelerated expiry by the Company upon 20 days' notice in the event the Common Shares trade at a price equal to or greater than $1.00 for a period of 20 consecutive trading days.
The CSE has approved the Common Shares for listing and has advised the Company that the Common Shares will commence trading on the CSE on or about December 19, 2017 under the ticker symbol "VIDA."
Canaccord Genuity Corp., as lead agent, together with Mackie Research Capital Corporation and Haywood Securities Inc. (collectively, the "Agents") acted as the Company's agents in connection with the Offering. Phivida recognizes Liberty North Capital and Hillcrest Capital Partners for their significant contributions as corporate advisors. Pursuant to the Offering, the Agents received a cash commission equal to 7% of the gross proceeds of the Offering, other than in respect of presidents list purchasers which was 3.5%, a corporate finance fee of $75,000 and 187,500 Common Shares, and compensation options exercisable in 832,563 Common Shares at a price of $0.40 per share for a period expiring 24 months from the closing date.
CEO John-David Belfontaine states; "The credit belongs to the hard work and professionalism of the Phivida board, executive and operations team. We also recognize our syndicate and advisory partner team for their contributions in stewarding a successful initial public offering. This is a significant achievement for The Company, but just the beginning of our shared success, as we prepare to launch our premium suite of Phivida brand CBD products onto a global stage in 2018. We look forward to providing more exciting updates and milestone achievements as we enter this rapid-growth phase in the life of Phivida."
The Company intends to use the proceeds from the Offering to begin full-scale manufacturing, marketing and distribution of Phivida Nutrition and Phivida Enhanced products. Phivida Nutrition products will consist of custom formulated hemp oil infused beverages that include a proprietary blend of nutraceuticals and infused with nanoencapsulated hemp oil extracts. Phivida Enhanced products will be marketed under the Vida+ brand name as functional foods and supplement nutraceuticals and capture a leadership share of the US CBD hemp oil market.
Phivida Holdings Inc.
Phivida (pronounced "fi-VEE-dah") is a premier brand of cannabidiol ("CBD")-infused functional foods, beverages and clinical products that is poised for global distribution. The World Anti-Doping Association's recent decision to lift its ban of CBD from hemp oil and the World Health Organization's recent statement that CBD is an effective treatment for epilepsy — and that there is some evidence that CBD could help treat Alzheimer's disease, cancer, psychosis, Parkinson's disease and other conditions opens the door for athletes and active families use Phivida products. Phivida's mission is to be a global leader in the alternative health sector while advancing education and research and investing back into our communities. For more information visit www.phivida.com
News 
Market Data 
Discover 
